H4Sio4
Orthosilicic acid
CAS: 10193-36-9
Molecular Formula: H4O4Si
H4Sio4 - Names and Identifiers
| Name | Orthosilicic acid |
| Synonyms | H4Sio4 MONOSILICICACID Orthosilicic acid tetrahydroxysilane Tetrahydroxysilicon Silicon tetrahydoxide Silicic acid (H4SiO4) SILICONTETRAHYDROXIDE |
| CAS | 10193-36-9 |
| EINECS | 233-477-0 |
H4Sio4 - Physico-chemical Properties
| Molecular Formula | H4O4Si |
| Molar Mass | 96.11 |
| Density | 2.63 g/cm3 |
| Boling Point | 153-156 °C(Press: 2 Torr) |
| Water Solubility | 100ng/L at 25℃ |
| Vapor Presure | 1.333hPa at 25℃ |
| Appearance | exists only in solution |
| pKa | 12.39±0.53(Predicted) |
| Use | Silicon hydroxide (Si(OH)4), commonly known as orthosilicic acid or orthosilicic acid (H4SiO4), a chemical, a hydrate of silicon dioxide (SiO2). H4SiO4 is unstable and easily decomposes into silicic acid (H2SiO3). When hydrochloric acid and Na2SiO3 solution react, a white colloidal precipitate is formed, which precipitates a polymer called orthosilicic acid. |
H4Sio4 - Preparation Method of orthosilicic acid
from Palm Bridge research
Application (patent) number:
CN 200810061695
application date:
May 29, 2008
Public/Announcement Number:
CN 101279737 A
applicant (patent):
Jiaxing Hongri Chemical Co., Ltd.
inventor:
Chen Huaimin , High increase , Qiu Jianfeng , Xu Pei
National and provincial code:
Zhejiang
cited:
Abstract:
The present invention relates to A preparation method of orthosilicic acid, the chemical formula of which is H4SiO4, and is characterized in that the following steps are adopted: A: 10-20 by weight ratio of SiO2 to water: 100 mixing, strong stirring, at 15 deg C, drop NaOH or KOH solution, to pH 8-9;B: under strong stirring, oil bath is heated to 50-55 deg C, reaction 2-3 hours to obtain a uniform solution; C: cooled to room temperature, with strong stirring, to the above homogeneous solution into CO2 gas, to pH 4;D: subsequently, choline chloride is added in a weight ratio of 20-45:100 to the solution obtained in Step C, and stirred for 10-20 minutes to obtain a stable orthosilicic acid solution, the silicon content of the orthosilicic acid solution is 2-2.5%. The preparation of orthosilicic acid has the advantages of low cost, environmental protection in the preparation process, no discharge of toxic and harmful substances in the preparation process, and the prepared orthosilicic acid solution has the advantages of versatility and long storage time.
stowed
sovereignty:
1. A method for preparing orthosilicic acid, wherein the chemical formula of the orthosilicic acid is H4SiO4, characterized in that the following steps are used: A) SiO2 and water are mixed at A weight ratio of 10-20: 100, naOH or KOH solution is added dropwise at at 15 °c to pH 8-9; B) with vigorous stirring, the oil bath is heated to 50-55 °c for 2-3 hours to obtain a homogeneous solution; C) cool the solution to room temperature, with vigorous stirring, CO2 gas is introduced into the above solution to PH ≤ 4; D) this is followed by the addition of choline chloride in a weight ratio of 20-45: 100 to the solution obtained in Step C), and stirring for 10-20 minutes to obtain a stable solution of orthosilicic acid.
Last Update：2024-01-02 23:10:35
H4Sio4 - Formulations including stable orthosilicic acid and biological agents
from Palm Bridge research
Application (patent) number:
CN 95192009
application date:
Feb 7, 1995
Public/Announcement Number:
CN 1049195 C
applicant (patent):
biopharmaceutical science companies
inventor:
National and provincial code:
Netherlands
cited:
Abstract:
The present invention relates to a formulation comprising orthosilicic acid, which is stabilized with a stabilizer and is substantially free of organosilicon compounds, preferably a nitrogen-containing stabilizer such as choline, to a process for the preparation of this formulation, the method comprises: I) providing a solution containing a stabilizer; ii) dissolving an inorganic silicon compound in the solution containing the stabilizer; And iii) hydrolyzing the silicon compound to orthosilicic acid, and relates to the biological agents obtained.
sovereignty:
1. An inorganic silicon compound-based formulation comprising ortho-silicic acid stabilized by at least one Silicic acid stabilizer, the stabilizers are quaternary ammonium compounds and/or amino acids.
Last Update：2023-08-16 22:05:47
H4Sio4 - Effect of polymer on decomposition behavior of calcium orthosilicate
from Palm Bridge research
Author:
Kaiwei Dong , Jiang Xiaojie , Zhang Shuang , pan Xiaolin , Yu Haiyan
Abstract:
aiming at the secondary reaction in alkali lime sintering process, the effect of different polymers on the decomposition behavior of calcium orthosilicate in sodium aluminate solution was studied by using analytical pure chemical reagents as raw materials, the mechanism was discussed by means of XRD and IR. The results showed that sodium polyacrylate (PAAS) and polyethylene glycol (PEG) could inhibit the decomposition of β-2CaO · SiO2 in sodium aluminate solution and decrease the concentration of SiO2 in solution; the inhibitory effect of PAAS and the 1:1 mixture of PAAS and PEG on the decomposition of β-2CaO · SiO2 was better than that of PEG. The polymer reduced the decomposition of β-2CaO · SiO2 by inhibiting the formation of calcium-silica slag; PEG inhibited the decomposition of β-2CaO · SiO2 by physical adsorption at the interface of β-2CaO · SiO2/sodium aluminate solution, while PAAS inhibited the decomposition of β-2CaO · SiO2 by chemical adsorption.
Key words:
calcium ortho-silicate polymer sodium aluminate solution silica calcium silica slag
year:
2013
Last Update：2023-08-16 22:05:47
H4Sio4 - Study on the mechanism of the effect of the non classical BMP pathway on the bone differentiation in vitro
Author:
Abstract:
research background Osteoporosis (OP) is a systemic skeletal disease characterized by low bone mass and destruction of bone microstructure, which leads to increased bone fragility and is prone to fracture. In the process of osteoporosis, the dynamic balance between bone formation and bone resorption is disordered, and a vicious circle is gradually formed, resulting in a significant increase in fracture susceptibility. At the same time, osteoporosis as a degenerative disease, its Incidence Rate is closely related to the increase of age, with the increase of human life and the aging of the population, osteoporosis has become a serious public health problem facing mankind. Therefore, the research on the treatment of osteoporosis and its complications has become the focus of the current research. As an important essential trace element in human body, silicon is closely related to the occurrence and development of osteoporosis. Silicon may act as vitamin D to significantly increase the rate of bone mineralization. Previous studies have found that the lack of silicon in the diet can easily lead to abnormal bone development and decrease bone density. Due to the low molecular weight and good water solubility of Orthosilicic Acid, Orthosilicic Acid is the most suitable form of silicon element to be absorbed by humans and animals. Recent studies have confirmed that bone morphogenetic protein (BMP) plays an important role in the process of osteogenic differentiation mediated by prosilicic acid, however, whether there are other non-classical BMP pathways involved in the process of osilicic acid-mediated bone differentiation has not yet been fully elucidated. Previous studies have repeatedly confirmed that PI3K-Akt-mTOR signaling pathway has a positive regulatory role in the process of osteogenic differentiation. However, the relationship between the process of osteogenic differentiation mediated by orthosilicic acid and the PI3K-Akt-mTOR signaling pathway has not been studied in the current field of bone differentiation. Therefore, the main content of this study is that orthosilicic acid acts on adipose-derived mesenchymal stem cells (ADMSCs) and human osteoblast-like cells (MG-63 and U2-OS), respectively. Then, the expression changes of related osteogenic indexes and PI3K-Akt-mTOR signaling pathway were detected to explore the effect of orthosilicic acid on bone differentiation of ADMSCs and human osteoblast-like cells and its relationship with PI3K-Akt-mTOR signaling pathway. At the same time, because ADMSCs have the potential of multi-directional differentiation, this study further detected the changes of RANKL/OPG signaling pathway, which is closely related to osteoclast differentiation, to explore the mechanism of action of ortho-silicic acid on ADMSCs in osteoclast differentiation. The innovation of this study: 1. For the first time to explore the role of orthosilicic acid in adipose mesenchymal stem cells and human osteoblast-like cells after the role of bone differentiation and the relationship between the PI3K-Akt-mTOR signaling pathway; 2. It is the first time that orthosilicic acid acts on adipose-derived mesenchymal stem cells, and explores the mechanism of orthosilicic acid in the process of bone differentiation from two aspects of osteogenic differentiation and Osteoclastic differentiation. The results of this study will provide clues for the combined application of orthosilicic acid and ADMSCs in the treatment of osteoporosis and its complications, and provide a new theoretical basis for the treatment of osteoporosis with orthosilicic acid. The first part of the study on the mechanism of the effect of the PI3K-Akt-mTOR pathway and the RANKL/OPG pathway on the bone differentiation of adipose mesenchymal stem cells in vitro. Objective (1) to detect the effect of the effect of the original Silicon acid on the cell activity of ADMSCs. (2) to detect the effect of the original Silicon acid on the bone differentiation of ADMSCs. (3) to explore the possible mechanism of the effect of ortho-silicic acid on the bone differentiation of ADMSCs. Research Methods (1) in order to verify the stability of the purchased ADMSCs, the osteogenic and adipogenic differentiation ability of the 6th generation of ADMSCs with good growth status was identified by alizarin Red S staining and oil Red O staining; at the same time, the surface specific markers of the sixth generation ADMSCs were identified by flow cytometry. (2) The cell activity of ADMSCs was detected by CCK-8 method after the application of different concentrations of silicon acid on the 1d, 3d, 5d, 7d of ADMSCs. (3) Wstern blot technique was used to detect the changes of osteogenic differentiation indexes (COL1 and RUNX2) after different concentrations of prosilicic acid acting on ADMSCs 7d, the relationship between the expression of COL1 and RUNX2 and the concentration of orthosilicic acid was analyzed, and the optimal concentration of orthosilicic acid for Inducing Osteogenic Differentiation of ADMSCs was explored. (4) using alizarin Red S staining method to detect the formation of calcium nodules after the action of prosilicate on ADMSCs 28d. (5) Wstern blot technique was used to detect the changes of PI3K-Akt-mTOR signaling pathway after different concentrations of prosilicic acid acting on ADMSCs 7d, and the relationship between the changes and the concentration of the original silicic acid was analyzed. (6) using cell immunofluorescence technique to detect the expression of P-Ak t and P-mTOR in the cells after the action of the original Silicon acid on the 7d of ADMSCs, and further verify the effect of the original Silicon acid on the PI3K-Akt-mTOR signaling pathway. (7) according to the presence or absence of orthosilicic acid and PI3K inhibitor LY294002, the cells were divided into the following 4 groups: control group, control + LY294002 group, orthosilicic acid group, orthosilicic acid + LY294002 group. Wstern blot was used to detect the expression of PI3K-Akt-mTOR signaling pathway and osteogenic differentiation indexes (COL1, RUNX2) in the 4 groups, the relationship between osteogenic differentiation of ADMSCs mediated by orthosilicic acid and PI3K-Akt-mTOR signaling pathway was analyzed. (8) according to the above grouping, the effect of orthosilicic acid and LY294002 on the expression of osteogenic differentiation index ALP was detected by BCIP/NBT alkaline phosphatase (ALP) chromogenic method, to further explore the relationship between the osteogenic differentiation of ADMSCs mediated by orthosilicate and the PI3K-Akt-mTOR signaling pathway. (9) Wstern blot technique was used to detect the expression of RANKL and OPG after different concentrations of prosilicic acid acting on ADMSCs 7d, the relationship between the expression of RANKL and OPG and the concentration of the original silicic acid was analyzed, and the concentration of the original silicic acid that best inhibited the differentiation of ADMSCs to osteoclasts was explored according to the ratio of RANKL/OPG. (10) the cells were divided into the following three groups according to the presence or absence of active protein sRANKL and orthosilicic acid: control group, sRANKL group, sRANKL + orthosilicic acid group. Wstern blot technique was used to detect the expression of related osteoclast differentiation indexes (NFATc1, CALCR, CTSK), and to analyze the role of protosilicic acid in sRANKL-mediated osteoclast differentiation of ADMSCs. (11) according to the above group, the effect of protosilicate and sRANKL on the expression of osteoclast differentiation index TRACP was examined by using tartrate resistant acid phosphatase (TRACP) staining method, the role of orthosilicic acid in sRANKL-mediated osteogenic differentiation of ADMSCs was further analyzed. Experimental results (1) the 6th generation of ADMSCs after osteogenic and adipogenic induction, the two staining results were positive; At the same time, the cell surface specific protein was identified by flow cytometry, the results showed that the positive rate of CD90 was more than 90%, and the positive rates of CD45 and CD11 were less than 5%. It indicates that ADMSCs have the ability of osteogenic and adipogenic differentiation, and have the surface characteristics of mesenchymal stem cells. (2) the cell activity of ADMSCs did not change with the change of the concentration and time of the original silicic acid. The results showed that orthosilicic acid (less than 40 M) had no significant effect on the cell activity of ADMSCs. (3) the expression of COL1 and RUNX2 can be up regulated by the original silica. When the concentration of prosilicic acid was 20 μm, the up-regulation of COL1 and RUNX2 was the most significant, which could be used as the optimal concentration of prosilicic acid to induce osteogenic differentiation of ADMSCs. (4) the effect of prosilicic acid (20 μm) on ADMSCs 28d can significantly promote the formation of calcium nodules. (5) the expression of PI3K, P-Akt and P-mTOR was up regulated by the original Silicon acid. When the concentration of the original Silicon acid was 20 M, the increase of P-Akt was the most significant. However, the expression of total Akt and total mTOR did not change significantly with the concentration of orthosilicic acid. (6) the number of fluorescence positive cells and fluorescence intensity of P-Akt and P-mTOR were significantly increased by the original silica acid. The results were consistent with the Wstern blot results. (7) the expression of PI3K, P-Akt, P-mTOR, COL1 and RUNX2 was up-regulated by orthosilicic acid. When the PI3K inhibitor LY294002 was added, the expression of the above proteins was down-regulated. The results showed that the osteogenic differentiation of ADMSCs was also inhibited by the inhibition of PI3K-Akt-mTOR signaling pathway. (8) orthosilicic acid can increase the expression of ALP, and when LY294002 is added, the expression of ALP is inhibited. The results were consistent with the other indicators of osteogenic differentiation (COL1 and RUNX2). It was confirmed again that the PI3K-Akt-mTOR signaling pathway plays a positive regulatory role in the process of osteogenic differentiation of ADMSCs mediated by prosilicic acid. (9) the expression of RANKL and up regulation of OPG can be down regulated by the original Silicon acid. This result indicates that orthosilicic acid inhibits the differentiation of ADMSCs into osteoclasts by reducing the ratio of RANKL/OPG. When the concentration of 20 u M, the ratio of RANKL/OPG was the lowest, which could be used as the optimal concentration to inhibit the differentiation of ADMSCs into osteoclasts. (10)sRANKL can up-regulate the expression of osteoclast differentiation indicators NFATc1, CALCR and CTSK. When orthosilicic acid is added together, the expression of the above indicators is down-regulated. These results indicate that the prosilicic acid can inhibit the osteoclast differentiation process of ADMSCs mediated by sRANKL. (11)sRANKL can enhance the positive reaction of TRACP staining and increase the number of positive cells. When orthosilicic acid is added together, the positive reaction of TRACP staining is weakened and the number of positive cells is reduced. This result reconfirms that orthosilicic acid can inhibit the osteoclast differentiation process mediated by sRANKL. The experimental conclusion (1) prosilicic acid (less than or equal to 40 M) had no significant effect on the cell activity of ADMSCs. (2) the expression of the indicators of osteogenic differentiation (RUNX2, COL1 and ALP) was up regulated by the original silica, which promoted the osteogenic differentiation of ADMSCs. (3) orthosilicic acid can activate the PI3K-Akt-mTOR signaling pathway in the process of osteogenic differentiation of ADMSCs. When this pathway is inhibited, the process of osteogenic differentiation is also inhibited, indicating that the PI3K-Akt-mTOR signaling pathway plays a positive regulatory role in the osteogenic differentiation of ADMSCs mediated by prosilicic acid. (4) the expression of RANKL and up regulated OPG, decreased the ratio of RANKL/OPG, and inhibited the differentiation of ADMSCs into osteoclasts. (5) orthosilicic acid can inhibit the osteoclast differentiation of ADMSCs mediated by the active protein sRANKL, and make the related osteoclast differentiation indexes (NFATc1, CALCR,CTSK and TRACP) Down-regulation of expression. This result further indicates that orthosilicic acid can not only reduce the expression of RANKL, but also inhibit the Osteoclastic differentiation mediated by RANKL. The second part of the original silicic acid in vitro through the P13K-Akt-mTOR pathway to promote human osteoblast like cells into bone and its mechanism research objective (1) to detect the effect of original silicic acid on two kinds of human osteoblast like cells (MG-63 and U2-OS) the effect of cell activity. (2) to detect the osteogenic effect of orthosilicic acid on human osteoblast-like cells. (3) to explore the relationship between osteogenic process mediated by orthosilicic acid and PI3K-Akt-mTOR signaling pathway. Methods (1) different concentrations of orthosilicic acid were used to act on MG-63 and U2-OS 72h respectively, and the cell activity was detected by CCK-8 method. (2) Wstern blot technique was used to detect the changes of osteogenic indexes (COL1 and RUNX2) after different concentrations of orthosilicic acid acting on MG-63 and U2-OS 72H, the relationship between the expression of COL1 and RUNX2 and the concentration of orthosilicic acid was analyzed, and the optimal concentration of orthosilicic acid to promote the Osteogenesis of two human osteoblast-like cells was explored. (3) cell immunofluorescence technique was used to detect the expression of MG-63 and U2-OS in the cells after P-Akt and P-mTOR 72h, and to explore the effect of the PI3K-Akt-mTOR signaling pathway. (4) according to the presence or absence of orthosilicic acid and LY294002 cells are divided into such as
stowed
Key words:
osteoporosis orthosilicic acid adipose-derived mesenchymal stem cells bone differentiation PI3K-Akt-mTOR RANKL/OPG osteogenesis
Last Update：2023-08-16 22:05:47
H4Sio4 - Reference Information
| LogP | -1 at 25℃ |
| EPA chemical information | Information provided by: ofmpub.epa.gov (external link) |
Last Update：2024-04-10 22:29:15
Supplier List
Product Name: Orthosilicic acid Request for quotation
CAS: 10193-36-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 10193-36-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
Product Name: Orthosilicic acid Request for quotation
CAS: 10193-36-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
CAS: 10193-36-9
Tel: 0086-551-65418684
Email: sales@tnjchem.com
info@tnjchem.com
Mobile: 0086 189 4982 3763
QQ: 2881500840
Wechat: 0086 189 4982 3763
WhatsApp: 0086 189 4982 3763
Product List: View Catalog
View History